

COMPANY ANNOUNCEMENT

CTA commences First Time in Human Clinical Trial with Bionomics Ltd

15th January 2008, Melbourne Australia. Cancer Trials Australia (CTA) announced today that it had entered into an agreement with Bionomics Ltd to conduct a first time in human study (FTIH) with Bionomics' new investigational drug, BNC105, a Novel Vascular Disrupting Agent.

“Bionomics is one of Australia’s leading biotechnology companies and it’s great to see them taking the decision to utilise the expertise that is available locally to assist them in this phase of their development program for BNC105”, said Mr Marcus Clark, CEO of CTA.

The trial design is an accelerated two-stage, dose escalation study in patients with advanced solid tumours. Bionomics and CTA will conduct the first stage of the study at the Royal Melbourne Hospital, Peter MacCallum Cancer Institute and Western Hospital. For the second stage, the Austin Hospital may also participate thereby including all current CTA members in the development.

“Bionomics obtained approval for its IND from the FDA at the end of last year to conduct the study in Australia and we are very happy to be undertaking this pivotal study with the CTA group. CTA members are very experienced in early phase clinical trials and the oncologists involved represent some of the very best in the field. We look forward to enrolling the first patient shortly. This trial has been meticulously designed and will provide a large amount of data as a foundation for our ongoing development of BNC105. We are excited by the prospects of BNC105 for the treatment of a range of cancers”, said Deborah Rathjen, CEO of Bionomics.

About Cancer Trials Australia (CTA)

CTA is a not-for-profit Clinical Site Advisory Organisation providing access to clinical trials sites, research governance, advisory and laboratory assay services to investigators and sponsors of clinical trials in the field of oncology. Its member’s organisations are:

Austin Health
Ludwig Institute for Cancer Research
Melbourne Health
Peter MacCallum Cancer Centre
The Walter and Eliza Hall Institute
Western Hospital